Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

J&J expects inflation, China COVID hit to carry into 2023

Stock Markets Jan 24, 2023 01:44PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. The U.S. flag is seen over the company logo for Johnson & Johnson to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid
 
JNJ
-0.39%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Bhanvi Satija and Manas Mishra

(Reuters) - Johnson & Johnson (NYSE:JNJ) on Tuesday said it sees the impact from high inflation carrying into 2023 and expects China's major COVID-19 outbreak to dent sales at its medical devices unit in the first half of the year.

Inflation has hurt demand for consumer health products and driven up costs for the healthcare conglomerate.

The J&J forecast and comments on the COVID disruption to business in China point to issues likely to hurt the entire medical technology sector in the first half of the year, Truist Securities analyst Richard Newitter said in a note.

"Expect this will get called out by other MedTech companies when they issue their 2023 outlooks as well," he said.

J&J forecast 2023 sales of $96.9 billion to $97.9 billion, putting the midpoint of the range below Wall Street estimates, while fourth-quarter profit came in ahead of expectations due to cost management and strong demand for some prescription medicines despite lower-than-expected medical device sales.

"Given all the macroeconomic uncertainty, geopolitical uncertainty, we thought this was the right approach at this point in time to come out with guidance in the ranges that we did," Chief Financial Officer Joseph Wolk said on a conference call.

J&J shares were down more than 1% in midday trading.

Sales of some key treatments, such as Crohn's disease drug Stelara, missed analyst estimates. But COVID-19 vaccine sales exceeded diminished expectations and demand for cancer drug Darzalex helped drive the fourth-quarter profit beat.

The company reported $689 million in quarterly COVID-19 vaccine sales from outside the United States.

"If there was one bit of disappointment in the quarter, it was that COVID-19 vaccine sales were stronger than expected and masked some of the underperformance we saw in some larger drugs," said Edward Jones analyst John Boylan.

J&J said it expects U.S. sales of Stelara to be flat to lower in 2023 due to competition from less expensive biosimilars in certain regions.

It forecast adjusted 2023 earnings of $10.45 to $10.65 per share, above analysts' estimates of $10.35.

Pharmaceutical sales of $13.16 billion for the fourth quarter edged past estimates of $13.14 billion, helped by $2.08 billion in Darzalex sales. Analysts were expecting $2.02 billion for the drug.

GRAPHIC: Sales at J&J's Pharmaceuticals Unit (https://www.reuters.com/graphics/JOHNSONJOHNSON-RESULTS/zgvobrxkwpd/chart.png)

J&J also recorded $821 million in COVID-19 vaccine-related costs, which were related to changes in its research program and manufacturing capacity.

Excluding items, J&J earned $2.35 per share for the quarter, topping analysts' estimates by 12 cents, according to IBES data from Refinitiv.

J&J expects inflation, China COVID hit to carry into 2023
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email